Ardelyx Amends 2017 Agreement with Kyowa Kirin for Tenapanor to Treat Hyperphosphatemia in Japan
Shots:
- In the 2017 agreement, Ardelyx received $30M up front & $130M in milestones along with royalties. Kyowa Kirin gets exclusive rights to develop & commercialize tenapanor for hyperphosphatemia in Japan
- In the amended agreement, the companies reported a reduction in the royalty rate where Ardelyx to receive ~ $40M in 2 parts i.e., Kyowa Kirin's filing with the MHLW of its application for marketing approval of tenapanor and approval to market tenapanor for hyperphosphatemia in Japan
- Kyowa Kirin finalizes its P-III clinical program of tenapanor for hyperphosphatemia. Ardelyx has disclosed its current expectation to file for approval of tenapanor with MHLW in H2’22 with an expected decision in H2’23
Ref: PR Newswire | Image: Ardelyx
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
